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Letter to the Editor
MET mutations are associated
with aggressive and
radioresistant brain metastatic
non-small-cell lung cancer
The onset of brain lesions resulting from non-small-cell lung
cancer (NSCLC) is associated with a poor prognosis, with only
5% of patients surviving beyond the first year after diagnosis.1
Only a minority of carefully selected patients can be recom-
mended for surgical resection of brain metastases.2 Palliative
brain radiotherapy (BRT) could be efficacious in improving
symptoms and quality of life.3
However, growing evidence demonstrates that inappropri-
ate execution of the MET-driven “invasive growth” program is
implicated in the metastatic process and that MET overexpres-
sion promotes radiation-induced tumor invasiveness.4,5
Here, we assessed the METmolecular status in a relevant se-
ries of surgical samples from primary NSCLC, along with the
corresponding brain metastases, in order to decipher the role
of MET in predicting patients’ outcomes and radiotherapy
responsiveness.
A total of 68 NSCLC samples and their matched brainmetas-
tases were retrieved from consecutive cohorts from the
archives of the pathology divisions of the University of Turin
at the Citta` della Salute e della Scienza, Molinette Hospital of
Turin and of San Luigi Hospital, Orbassano, Italy. The study re-
ceived ethical approval from local institutional review boards.
Each sample was independently reviewed by 2 dedicated pathol-
ogists (R.S. and P.C.), who confirmed all diagnoses according to
the current World Health Organization classification.6 We ana-
lyzed the entire coding sequence ofMET, together with gene am-
plification by fluorescence in situ hybridization analysis, as already
described.7 Age, gender, and radiotherapy of primary tumor and
brain metastases, histotypes, and survival were ascertained for
each case. Descriptive statistics were produced for demographic,
clinical, and laboratory characteristics of cases. Cox regression
was used to determine the association of patients’ characteristics
with survival following diagnosis of brain metastases.
The cohort analyzed was characterized as follows. Of the 68
cases, 15 were female (22%) and 53 were male (78%); the
mean age at diagnosis was 63.2+9.1 years; the cumulative
follow-up was 1438 patient-months, with amedian overall sur-
vival of 12 months (interquartile range, 7–39). The adenocarci-
noma histotype was represented in 54.4% of cases (37
patients); squamous cell carcinoma was detected in 20.5% of
cases (14 patients), whereas neuroendocrine lineage occurred
in 10.2% of cases (7 patients). The remaining 10 patients dis-
played undifferentiated carcinomas. All the studied patients
underwent surgical removal of both the primary mass and
the brain metastasis. Brain surgery followed the removal of
the primary mass (from 1 to 15 mo); in one case the brain le-
sion was diagnosed and removed 1 month before the appear-
ance of the primary lung tumor. Of all the patients, 73.5% (50
patients) underwent BRT after surgery.
In line with reported data (COSMIC database, http://cancer.
sanger.ac.uk/cosmic), somatic MET mutations occurred in
4.41% (3) of primary lung tumors; 19.12% of those samples
(13) harbored an increased MET gene copy number. We then
investigated the MET molecular profile of metastatic brain
lesions. Unexpectedly, 7.35% of patients (5) displayed activating
MET mutations, while 22.39% of lesions (15 patients) were MET
amplified. Two cases harbored mutations in both the primary
and themetastatic lesion. Coexistence ofMETmutation and am-
plificationwas not detected in any of the analyzed cases. Related
clinical and molecular data are shown in detail in Table 1.
Notably, themortality rate after BRTwas significantly higher in
tumors carrying MET somatic mutations compared with euploid
MET wild-type lesions (hazard ratio, 4.39; 95% CI, 1.46–13.18;
P, .008).
Overall, our findings have documented that the occurrence
of MET mutations in brain metastasis from NSCLC neutralized
the favorable effect of BRT, thus predicting a worse patients’
outcome. Although preliminary, our findings are coherent
with published data suggesting that MET targeting may impair
radioresistance.8 Moreover, for the first time, our results
strongly indicate that MET activation by somatic mutations is
associated with substantial radioresistance of highly invasive
NSCLC. The above described MET mutations have 2 clinical im-
plications: (i) a potential functional marker of highly aggressive
lung tumors, easily detectable in the near future by the “liquid
biopsy” approach9; (ii) a rationale for clinical trials with MET in-
hibitors in patients carrying advanced brain metastatic disease,
directed to radiotherapy.
Funding
This work was supported by a grant from “Fondi di Ricerca Locale
ex-60% 2013” to P.C.
Giulia Maria Stella, Rebecca Senetta, Simona Inghilleri,
Ludovica Verdun di Cantogno, Cristina Mantovani,
Davide Piloni, Luigia Scudeller, Federica Meloni,
Mauro Papotti, Umberto Ricardi, and Paola Cassoni
Cardiothoracic and Vascular Department, Pneumology Unit,
IRCCS Policlinico San Matteo Foundation, Pavia, Italy (G.M.S.,
Received 21 October 2015; accepted 28 December 2015
# The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
Neuro-Oncology
Neuro-Oncology 18(4), 598–599, 2016
doi:10.1093/neuonc/nov325
Advance Access date 23 February 2016
598
 at U
niversity of Torino on M
ay 20, 2016
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
S.I., D.P., F.M.); Department of Medical Sciences, Pathology
Section, University of Torino, Torino, Italy (R.S., L.V.d.C., P.C.);
Department of Oncology, Radiation Oncology, University of
Torino, Torino, Italy (C.M., U.R.); Clinical Epidemiology and
Biometric Unit, Scientific Direction, IRCCS Policlinico San
Matteo Foundation, Pavia, Italy (L.S.); Department of Oncology,
University of Torino, Torino, Italy (M.P.)
Corresponding Author: Giulia Maria Stella, MD, PhD, Cardiotho-
racic and Vascular Dept., Pneumology Unit, IRCCS Policlinico
San Matteo Foundation, Piazzale Golgi 19, 27100, Pavia, Italy
(g.stella@smatteo.pv.it).
Acknowledgment
The authors thank Dr Radhika Srinivasan for careful revision of the
manuscript.
Conflict of interest statement. None declared.
References
1. D’Addario G, Fruh M, Reck M, et al. Metastatic non-small-cell
lung cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 2010;21(suppl 5):
v116–v119.
2. Hatiboglu AM, Wildrick DM, Sawaya R. The role of surgical resection
in patients with brain metastases. Ecancermedicalscience. 2013;7:
308.
3. Zabel A, Debus J. Treatment of brain metastasis from
non-small-cell lung cancer (NSCLC): radiotherapy. Lung Cancer.
2004;45(suppl 2):S247–S252.
4. Bertotti A, Comoglio PM, Trusolino L. MET signalling: principles and
functions in development, organ regeneration and cancer. Nat Rev
Mol Cell Biol. 2010;11(12):834–848.
5. Comoglio PM, Giordano S, Trusolino L. Drug development of MET
inhibitors: targeting oncogene addiction and expedience. Nat Rev
Drug Discov. 2008;7(6):504–516.
6. Travis WD, Brambilla E, Muller-Hermelink KM. WHO Classification
of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC
Press; 2004.
7. Stella GM, Benvenuti S, Gramaglia D, et al. METmutations in cancers
of unknown primary origin (CUPs). Hum Mutat. 2011;32:44–50.
8. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing
radiation and its role in radioresistance and invasive growth of
cancer. J Natl Cancer Inst. 2011;103(8):645–646.
9. Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy:
monitoring cancer-genetics in the blood. Nat Rev Clin Oncol.
2013;10(8):472–484.
Table 1. Clinico-pathological and molecular profile of the MET-mutated brain metastases
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5
Gender M M F F F
Age at diagnosis (y) 56 80 59 43 69
Histotype U LCNE ADC ADC ADC
Brain metastatic site Parietal lobe (r) Frontal lobe Parietal lobe (r) Sella Cerebellum
Number of brain lesions 1 1 1 1 1
MET mutational status
Lung T1010I Wt Wt Wt Wt
Brain T1010I E168D E168D E168D T1010I
MET copy number
Lung 2 2 2 2 2
Brain 2 2 2 2 2
EGFR exon 18–21 Wt Wt Wt Wt Wt
KRas exon 2 Wt Wt Wt Wt Wt
Overall survival (mo) 7 2 9 40 7
TtP (mo) 5 0 1 39 2
Survival from metastasis (mo) 2 2 1 1 4
Radiotherapy
Lung No No Yes No No
Brain Yes Yes Yes Yes Yes
Type of radiotherapy Stereotactic Stereotactic Stereotactic Stereotactic Stereotactic
Abbreviations: U, undifferentiated carcinoma; ADC, adenocarcinoma; LCNE, large-cell neuroendocrine carcinoma; TtP, time to progression; EGFR,
epidermal growth factor receptor; Wt, wild type; KRas, Kirsten rat sarcoma viral oncogene homolog.
All the MET mutations were found clustered either in the juxtamembrane or in the extracellular semaphorin domain of the receptor. Both the
T1010I and the E168D changes are already established somatic mutations, previously reported in both non-small- and small-cell lung cancers,
displaying documented tumorigenic potential. None of theMET-mutated patients underwent chemotherapy after surgical removal of both prima-
ry and secondary lesions.
Letter to the Editor
Neuro-Oncology 599
 at U
niversity of Torino on M
ay 20, 2016
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
